Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE: CRL) has partnered with Cypre, Inc. to enhance its 3D in vitro testing services. The collaboration grants access to Cypre's Falcon-X™ platform, a 3D tumor model technology that replicates the tumor microenvironment for better therapeutic efficacy predictions. This addition bolsters Charles River's existing cancer assay portfolio, facilitating more effective testing of immunotherapies and targeted treatments using a robust database of over 700 tumor models. The aim is to address cancer immunotherapy resistance and advance drug development.
Charles River Laboratories (NYSE: CRL) has formed a strategic partnership with JADE Biomedical to enhance its biologics testing capabilities. This collaboration aims to support the rising demand for biologics therapeutics, particularly in cell and gene therapies. JADE will expand its GMP product testing operations in Shanghai by opening a second facility, thereby increasing capacity for clients. The partnership combines both companies' expertise in navigating the complex global regulatory landscape, making them reliable partners to clients of any size.
Charles River Laboratories (NYSE: CRL) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12th at 10:00 a.m. EST. The management team will discuss the company's strategic focus, recent business developments, and industry trends. A live webcast will be accessible in the Investor Relations section of their website, with a replay available for two weeks thereafter.
Charles River supports pharmaceutical and biotechnology companies, government agencies, and academic institutions in their research and drug development efforts. For more details, visit their website.
Charles River Laboratories (NYSE: CRL) acquired Distributed Bio, Inc. on December 31, 2020, following a partnership initiated in October 2018. Located in South San Francisco, Distributed Bio specializes in next-generation antibody discovery. This acquisition enhances Charles River's capabilities, integrating Distributed Bio’s innovative platforms for therapeutic antibody and gene therapy development. The deal, valued at $83 million plus contingent payments of up to $21 million, is not expected to materially affect financial results in 2021. Distributed Bio is projected to contribute approximately $15 million in annual revenue.
Charles River Laboratories International (NYSE: CRL) has launched the first Good Laboratory Practices (GLP) validated digital peer review service using Deciphex Patholytix Preclinical. This innovative approach allows remote scanning and sharing of slides, enhancing efficiency and reducing study timelines. The partnership with Deciphex aims to modernize toxicologic pathology processes, especially crucial amid COVID-19 travel restrictions. The digital peer review process promises to deliver reliable data and streamline operations, ultimately benefiting clients with cost savings and improved service delivery.
PathoQuest SAS and Charles River Laboratories have announced the establishment of a U.S. subsidiary, PathoQuest, Inc., along with a new next generation sequencing (NGS) testing laboratory in Wayne, PA. This initiative aims to enhance rapid viral safety testing for biologics, including advanced therapeutic medicinal products (ATMPs) and vaccines. The facility will align with PathoQuest's Paris lab and will adhere to CGMP standards. Construction is set to begin late 2020, with services expected in 2021, bolstering North American biotech companies’ testing capabilities.
Charles River Laboratories International, Inc. (NYSE: CRL) will present at three virtual investor conferences. Key dates include the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 10:15 a.m. EST, the Jefferies Virtual London Healthcare Conference on November 18 at 2:40 p.m. GMT, and the Evercore ISI 3rd Annual HealthCONx Conference on December 2 at 9:40 a.m. EST.
Management will discuss strategic focus and business developments. Live webcasts will be available on the Investor Relations section of the Charles River website, with replays accessible for two weeks post-event.
Charles River Laboratories International, Inc. (NYSE: CRL) has appointed George Llado as a new member of its Board of Directors. Llado, who previously served as Senior Vice President and CIO at Alexion Pharmaceuticals, brings over 30 years of IT and cybersecurity experience in the biopharmaceutical sector. He will serve on the Corporate Governance and Nominating Committee, as well as the Compensation Committee. His expertise is expected to enhance Charles River's digital strategies and improve client experiences.
Charles River Laboratories (NYSE: CRL) is set to announce its third-quarter 2020 financial results on October 29, 2020, prior to market opening. A conference call will occur at 9:30 a.m. ET on the same day, allowing investors to gain insights directly from company executives. The call will be accessible via a live webcast on the Investor Relations section of their website, with a replay option available.